Merck's Bridion Approval Carries Several Post-Market Requirements
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck must conduct studies to determine likely non-responders, assess occurrence of hypersensitivity or anaphylaxis, evaluate risk of cardiac arrhythmias, and study sugammadex's effects in morbidly obese patients.